Press releases

System includes first directional lead with current steering and expanded programming flexibility

Boston Scientific will participate in the Morgan Stanley healthcare conference on Sept. 17, 2015. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on Sept. 9, 2015. Learn how to watch the webcast or replay.

Updated labeling allows backwards-compatibility for MRI scans for the industry's longest-lasting ICD and CRT-D systems

U.S. launch underway for therapy designed to treat Peripheral Artery Disease

Men’s health and prostate health acquisition positions Boston Scientific as a urology leader

Strategic alliance to expand Boston Scientific portfolio of remote monitoring solutions

"Our strong performance in the second quarter reflects the consistent execution of our global teams," said Mike Mahoney, CEO of Boston Scientific.

First guidewire designed specifically for TAVI/R now sized for smaller ventricles

First Patients Enrolled in the FAST Feasibility Study

Chairman Pete Nicholas welcomes James as a business leader with “significant financial knowledge, HR management and organizational planning skills.”

Demonstrates growing clinical acceptance for novel, procedure-based treatment option for severe asthma

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ending June 15, 2015. Learn how to tune in.

Study to evaluate patients implanted with S-ICD for primary prevention of sudden cardiac death in the setting of severely reduced cardiac function

Spinal cord stimulator (SCS) system provided 1.5x better overall pain relief and 2x better low back pain relief than previous generation system

World's smallest 16-contact high-capacity primary cell device expands spinal cord stimulator system (SCS) offering

Boston Scientific will participate in the healthcare conference on June 9, 2015. Learn how to watch the webcast or replay.

Compelling results presented at EuroPCR 2015 add to growing body of evidence supporting performance and safety

Additional data from EVOLVE II pivotal trial demonstrate safety and performance in patients with diabetes at one year

Boston Scientific Corporation (NYSE: BSX) announced its completed public offering of senior notes

Key data from 42 abstracts to include presentations on the WATCHMAN device and the EMBLEM S-ICD system.

Boston Scientific Corporation (NYSE: BSX) announced its pricing of a public offering of senior notes

Recognition from Shingo Institute is the second in two years for a company facility

CEO Mike Mahoney will outline company's unique opportunities to bring forward meaningful innovation

Customized programs to drive operational and care pathway improvements